A global pharmaceutical company with headquarters in Japan was using the services of another vendor to submit cases that occurred in Japan (domestic) and cases that occurred outside of Japan (foreign cases) to the PMDA. The company explored several options. Due to Bioclinca’s strong pharmacovigilance expertise and high quality, the company decided to partner with Bioclinica for their end-to-end case processing needs.